RNA-seq profile of stimulated Tregs containing co-receptor signaling domain variant chimeric antigen receptors (CARs).

Initial CAR therapies were designed and tested in conventional T cells, however several recent reports indicate that CAR Tregs may be effective in solid organ transplant or hematopoietic stem cell transplant. Since Tregs have different activation requirements, we sought to characterize the transcriptional profile of Tregs that were transduced with second-generation CARs containing various co-receptor signaling moieties to determine which bestows Tregs with the most desireable properties. Human Tregs/Tconv were transduced with second-generation chimeric antigen receptors (CARs) that contain various co-receptor signaling domains, then stimulated via CAR or T cell receptor.